Drug interactions
Canagliflozin-metformin + Erdafitinib
Severity: Moderate
Canagliflozin-metformin and Erdafitinib: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Metformin is an OCT2 substrate, and erdafitinib labeling flags OCT2 substrates as potentially affected. Erdafitinib may inhibit renal transporters, raising metformin exposure and the risk of its adverse effects.
What this interaction means in plain words
Canagliflozin-metformin and Erdafitinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Canagliflozin-metformin belongs to Endocrine; Erdafitinib belongs to Oncology.
Why it happens
Erdafitinib inhibits OCT2-mediated renal secretion of metformin.
What to do
Monitor for gastrointestinal intolerance and renal function, and consider reducing the metformin dose if adverse effects occur.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Canagliflozin-metformin and Erdafitinib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Canagliflozin-metformin
Other interactions of Erdafitinib
Frequently asked questions
Can I take Canagliflozin-metformin with Erdafitinib?
MediHelp rates the interaction as moderate. Canagliflozin-metformin and Erdafitinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Metformin is an OCT2 substrate, and erdafitinib labeling flags OCT2 substrates as potentially affected. Erdafitinib may inhibit renal transporters, raising metformin exposure and the risk of its adverse effects.
How serious is the interaction between Canagliflozin-metformin and Erdafitinib?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor for gastrointestinal intolerance and renal function, and consider reducing the metformin dose if adverse effects occur.
What other medicines interact with Canagliflozin-metformin?
MediHelp also lists interactions of Canagliflozin-metformin with, for example, Contrast media, Diatrizoate, Diatrizoate meglumine / diatrizoate. The full list is on the Canagliflozin-metformin page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
